RecruitingNot applicableNCT06627309

Rapid dFLC Response Predict CHR in AL Amyloidosis

Studying Primary systemic amyloidosis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Peking University People's Hospital
Principal Investigator: Yang Liu, M.D.
Intervention: Dara IV(drug)
Enrollment: 50 enrolled
Eligibility: 18-99 years · All sexes
Timeline: 2024 – 2026

Study locations (8)

Peking University People's Hospital, Beijing, Beijing Municipality, China
Fuxing Hospital affiliated to Capital Medical University, Beijing, Beijing Municipality, China
Beijing Anzhen Hospital, Beijing, Beijing Municipality, China
Peking University First Hospital, Beijing, Beijing Municipality, China
First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Chinese PLA Eastern Theater General Hospital, Nanjing, Jiangsu, China
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06627309 on ClinicalTrials.gov

Other trials for Primary systemic amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Primary systemic amyloidosis →

← Back to all trials